Emerging Regulations of AI - The Impact on Pharma R&D

Most recently both the EU and the US announced new legislation aiming to regulate the development and use of Artificial Intelligence: the EU AI Act and the President Biden Executive Order on the Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence. Our panel of experts will discuss how these legal changes may affect research and development in drug discovery.

Agenda

Introductions

• Vladimir Makarov, Project Manager, Pistoia Alliance

How is AI used in your organization?

Review of current and proposed regulations

Panel Discussion with our speakers

Speakers

• Frederik van den Broek, Senior Director, Professional Services and Consulting, Elsevier
• Koen Cobbaert, Senior Manager – Quality, Standards & Regulations, Philips
• Sophie Ollivier, Chief Data Officer R&D, Servier
• Gideon Rosenthal, Head of Research, Data Science Group

Closing Remarks and next steps

Please complete the form below to access a recording of the webinar and download the presentation slides